Affiliation:
1. Scientific and Research Rheumatology Institute n.a. V.A. Nasonova
2. North-Western State Medical University named after I.I. Mechnikov; Saint-Petersburg State Healthcare Institution “Clinical Rheumatology Hospital #25”
Abstract
Bisphosphonates are the main class of drugs for treatment osteoporosis (OP) and other diseases with increased bone resorption, as bisphosphonates are very effective in reducing risk of fracture. The problem of maintaining the effectiveness and possible loss of effect of bisphosphonates, as well as their safety during long-term use, remains actual Long-them therapy with bisphosphonates and it’s effects has been discussed over the past 20 years, as the risk of osteoporotic fracture may stay hight in patients with presence of irreducible risk factors (continous use of glucocorticoids etc.) despite ongoing antiosteoporotic therapy. Real clinical practice demonstrates very low patient adherence to treatment with bisphosphonates. However, observational studies have showed that treatment with bisphosphonates for more than 10 years without initiating a drug holiday can be effective for patients at high risk of fracture. Moreover, the longer therapy with bisphosphonates is continued and the later the“drug holiday”is initiated, the lower the risks of fractures of the proximal femur and clinical vertebral fractures. However, the duration of continuous bisphosphonate therapy for each patient remains at the decision of the physician and is determined individually in each case, based on the risk-benefit ratio, taking into account the patient’s risk factors for fractures and comorbid diseases.
Publisher
Endocrinology Research Centre
Reference29 articles.
1. Белая Ж.Е., Белова К.Ю., Бирюкова Е.В. и др. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза // Остеопороз и остеопатии. 2021;24(2):4-47
2. Kanis JA, Cooper C, Rizzoli R, Reginster JY. Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019 Jan;30(1):3-44
3. Сафонова Ю.А., Зубкова И.И., Зоткин Е.Г. Влияние обучающих программ на приверженность пациентов рекомендациям по профилактике и лечению остеопороза // Российский семейный врач. 2009;(1):32-35
4. Добровольская О.В. и соавт. Приверженность терапии комбинированным препаратом кальция и витамина D при разных режимах дозирования // Фарматека. 2011;(10):10-13
5. Khosla S, Shane E. A crisis in the treatment of osteoporosis. J Bone Miner Res. 2016; 31:1485-87
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献